How to Get Farxiga (Dapagliflozin) in Illinois

What Farxiga Does and Why Illinois Clinicians Prescribe It

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule of the kidney, lowering blood sugar while promoting modest natriuresis and osmotic diuresis 1. The FDA approved Farxiga for type 2 diabetes in 2014 and later expanded its label to include heart failure with reduced ejection fraction in 2020 and chronic kidney disease in 2021 2.

The clinical evidence behind these approvals is large-scale. In the DAPA-HF trial (N=4,744), dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74; 95% CI 0.65-0.85; P<0.001) compared to placebo, with benefits observed in patients both with and without diabetes 3. The DAPA-CKD trial (N=4,304) showed a 39% relative risk reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death 4. These results changed practice. The 2022 ADA Standards of Medical Care recommend SGLT2 inhibitors for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of baseline HbA1c or metformin use 5.

For Illinois prescribers, dapagliflozin offers a single daily tablet that addresses multiple cardiorenal endpoints. This is relevant in a state where cardiovascular disease remains the leading cause of death and CKD prevalence tracks national estimates of approximately 15% among adults 6.

Step-by-Step: Getting a Farxiga Prescription in Illinois

Getting started requires three things: a licensed prescriber, baseline labs, and a pharmacy. Here is how the process typically works.

1. Schedule a visit. Any Illinois-licensed MD, DO, NP, or PA can prescribe Farxiga. Under Illinois law (Public Act 103-0001), nurse practitioners hold full practice authority, meaning they can prescribe independently without a collaborative agreement 7. This expands access in rural counties where physician density is lower.

2. Complete baseline labs. Before prescribing dapagliflozin, clinicians typically order a basic metabolic panel (including serum creatinine and eGFR), HbA1c if the indication is diabetes, urinalysis, and a lipid panel. The KDIGO 2024 guidelines recommend checking eGFR and urine albumin-to-creatinine ratio (UACR) before initiating any SGLT2 inhibitor in CKD patients 8. Dapagliflozin can be initiated at eGFR as low as 20 mL/min/1.73 m², per the updated FDA label 2.

3. Submit the prescription. Your clinician sends the prescription electronically to your chosen pharmacy. If prior authorization is required, the prescriber's office handles the submission to your insurer (details below).

4. Pick up or receive delivery. Most chain and independent pharmacies in Illinois stock Farxiga. Mail-order options through Express Scripts, CVS Caremark, and OptumRx are available for 90-day supplies, which often carry lower per-unit copays.

Telehealth Access to Farxiga in Illinois

Illinois permits telehealth prescribing of Farxiga. The state's Telehealth Act (Public Act 102-0104, effective January 2022) requires that the prescriber hold an active Illinois license but does not mandate an in-person visit before issuing a prescription for a non-controlled substance like dapagliflozin 9. This aligns with AMA guidance supporting telehealth for chronic disease management 10.

A telehealth visit for Farxiga follows the same clinical workflow as an office visit. You will need recent lab results (within 90 days for most platforms). If you do not have labs, the telehealth provider can order them at a local draw site such as Quest Diagnostics or Labcorp, both of which operate multiple locations across Illinois.

Telehealth is especially practical for follow-up monitoring. The DECLARE-TIMI 58 trial protocol required lab checks at weeks 4, 8, and 16 after initiation 11, and most Illinois clinicians follow a similar cadence. Reviewing lab results via video visit saves a trip while maintaining oversight of renal function and electrolytes.

Illinois Medicaid and Prior Authorization for Farxiga

Illinois Medicaid (managed through the Illinois Department of Healthcare and Family Services) covers Farxiga with prior authorization. The PA requirement applies across all three approved indications: type 2 diabetes, heart failure, and CKD.

What documentation you need. PA submissions in Illinois typically require the following:

• A confirmed diagnosis with ICD-10 code (E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD)
• Evidence of trial or intolerance/contraindication to preferred agents (metformin for diabetes; ACE inhibitor or ARB for CKD)
• Recent labs: HbA1c, eGFR, UACR
• Clinical rationale citing guideline-concordant use

The 2022 AHA/ACC/HFSA heart failure guideline assigns a Class I recommendation (Level of Evidence A) to SGLT2 inhibitors for HFrEF regardless of diabetes status 12. Citing this guideline in a PA letter can strengthen the case for approval.

Turnaround time. Standard PA decisions in Illinois must be rendered within 24 hours for urgent requests and 72 hours for non-urgent requests, per state Medicaid rules. If denied, prescribers can file a peer-to-peer review or formal appeal.

Commercial insurance. Most Illinois commercial plans administered by Blue Cross Blue Shield of Illinois, Aetna, Cigna, and UnitedHealthcare cover Farxiga on formulary tiers 2 or 3. Step therapy requiring prior metformin use is common for the type 2 diabetes indication, though heart failure and CKD indications may be exempt from step therapy requirements given the Class I guideline status 12.

Cost, Copay Assistance, and Savings Programs

The average retail price for a 30-day supply of Farxiga 10 mg without insurance ranges from $550 to $620 at Illinois pharmacies. Several programs can reduce this cost significantly.

AstraZeneca savings card. Commercially insured patients may pay as little as $0 per fill with AstraZeneca's copay assistance program. The card covers up to $150 per 30-day fill, applicable for 24 months 2. It is not valid for Medicare, Medicaid, or other federal programs.

Medicare Part D. Farxiga is covered under most Medicare Part D formularies. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare beneficiaries have a $2,000 annual out-of-pocket cap on prescription drugs, which substantially reduces Farxiga costs for patients previously hitting the coverage gap 13.

Patient assistance. AstraZeneca's AZ&Me program provides Farxiga at no cost to uninsured or underinsured patients meeting income thresholds (typically <400% of the federal poverty level). The ACC and AHA have emphasized the importance of cost-reduction strategies for guideline-directed medical therapy adherence 14.

GoodRx and discount platforms. Cash-pay coupons through GoodRx or RxSaver can reduce the retail price to approximately $480 to $530 at Illinois pharmacies, depending on location.

Pharmacy Options in Illinois

Farxiga is widely stocked across Illinois. Options include:

Chain pharmacies. Walgreens (headquartered in Deerfield, IL), CVS, Walmart, and Jewel-Osco pharmacies carry Farxiga. Electronic prescriptions from telehealth providers route seamlessly to these locations.

Independent pharmacies. The Illinois Pharmacists Association lists hundreds of independent pharmacies statewide. These may offer competitive cash pricing and personalized medication counseling.

503A compounding pharmacies. Illinois-licensed 503A pharmacies can compound dapagliflozin for patients who need a non-standard dosage form (e.g., liquid suspension for patients with swallowing difficulty). Compounded versions require a patient-specific prescription and are regulated under the Illinois Pharmacy Practice Act 15. Note that 503A compounding of dapagliflozin is relatively uncommon since the commercial tablet is the preferred formulation in clinical trials 3.

Mail-order and specialty pharmacies. For 90-day supplies, mail-order through your insurance plan's preferred pharmacy (commonly Express Scripts, CVS Caremark, or OptumRx) often reduces per-unit cost. The DELIVER trial, which studied dapagliflozin in HFpEF (N=6,263), found that medication adherence above 80% was associated with maximal cardiovascular benefit 16. Mail-order fills reduce refill gaps and may improve adherence.

Monitoring and Follow-Up After Starting Farxiga

Starting dapagliflozin requires structured follow-up. Here is what to expect.

Week 2 to 4. Recheck serum creatinine and potassium. An initial eGFR dip of 10-30% is expected and considered hemodynamic, not structural kidney injury 17. The CREDENCE investigators and subsequent SGLT2 inhibitor analyses confirmed that this early dip does not predict long-term renal harm and in fact correlates with better long-term outcomes 4.

Month 3. Repeat HbA1c (if prescribed for diabetes), eGFR, UACR, and metabolic panel. The ADA recommends reassessing glycemic targets at 3 months to determine whether combination therapy adjustments are needed 5.

Ongoing. Every 3 to 6 months, monitor renal function, electrolytes, and volume status. Watch for signs of genital mycotic infections (occurring in approximately 5-7% of patients in DECLARE-TIMI 58) and urinary tract infections 11. Euglycemic diabetic ketoacidosis (DKA) is rare (<0.1% in trials) but should be considered in patients with nausea, vomiting, or abdominal pain, particularly during acute illness or perioperative periods 18.

Sick-day rules. The ABCD/Diabetes UK consensus recommends holding SGLT2 inhibitors during acute illness with vomiting, diarrhea, or reduced oral intake to minimize DKA risk 19. Educate every patient on this protocol at the time of prescribing.

Who Should Not Take Farxiga

Dapagliflozin is contraindicated in patients on dialysis and those with a history of serious hypersensitivity to the drug. The FDA label also carries warnings for necrotizing fasciitis of the perineum (Fournier gangrene), a rare but serious adverse event reported across the SGLT2 inhibitor class 2. The Endocrine Society's 2023 clinical practice guideline advises caution in patients with recurrent genitourinary infections and recommends against use in type 1 diabetes outside of clinical trials 20.

Prescribers should also assess volume status before initiation. Patients taking loop diuretics may require dose reduction of the diuretic when adding dapagliflozin to avoid hypotension. The DAPA-HF protocol reduced diuretic doses in 25% of enrolled patients during the first 8 weeks 3.